Mebicar

	WikiDoc Resources for Mebicar
Articles
Most recent articles on Mebicar Most cited articles on Mebicar Review articles on Mebicar Articles on Mebicar in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mebicar Images of Mebicar Photos of Mebicar Podcasts & MP3s on Mebicar Videos on Mebicar
Evidence Based Medicine
Cochrane Collaboration on Mebicar Bandolier on Mebicar TRIP on Mebicar
Clinical Trials
Ongoing Trials on Mebicar at Clinical Trials.gov Trial results on Mebicar Clinical Trials on Mebicar at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mebicar NICE Guidance on Mebicar NHS PRODIGY Guidance FDA on Mebicar CDC on Mebicar
Books
Books on Mebicar
News
Mebicar in the news Be alerted to news on Mebicar News trends on Mebicar
Commentary
Blogs on Mebicar
Definitions
Definitions of Mebicar
Patient Resources / Community
Patient resources on Mebicar Discussion groups on Mebicar Patient Handouts on Mebicar Directions to Hospitals Treating Mebicar Risk calculators and risk factors for Mebicar
Healthcare Provider Resources
Symptoms of Mebicar Causes & Risk Factors for Mebicar Diagnostic studies for Mebicar Treatment of Mebicar
Continuing Medical Education (CME)
CME Programs on Mebicar
International
Mebicar en Espanol Mebicar en Francais
Business
Mebicar in the Marketplace Patents on Mebicar
Experimental / Informatics
List of terms related to Mebicar

Mebicar
Legal status
Legal status	US: Not approved ;
Identifiers
	IUPAC name 1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione;
CAS Number	10095-06-4;
PubChem CID	122282;
ChemSpider	109042;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C8H14N4O2
Molar mass	198.222 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN1C2C(N(C1=O)C)N(C(=O)N2C)C;
	InChI InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3; Key:XIUUSFJTJXFNGH-UHFFFAOYSA-N;

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mebicar (mebicarum) is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in the Russian Federation under the brand name Adaptol.^[1] It is not approved for use in the United States or European Union.

Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.^[2]

Mebicar purportedly has anti-anxiety (anxiolytic) properties.^[2]^[3]^[4]^[5]^[6] It is also used to aid smoking cessation.^[1] In addition Mebicar may be useful in the treatment of ADHD symptoms.^[7] In contrast with typical anxiolytic medication like benzodiazepines Mebicar is non-habit forming, non-sedating and does not impair motor function.^[3]^[1]

References

↑ ^1.0 ^1.1 ^1.2 Adaptol product summary http://olainfarm.lv/en/prescription-drugs/adaptol-3
↑ ^2.0 ^2.1 Val'Dman, AV; Zaikonnikova, IV; Kozlovskaia, MM; Zimakova, IE (1980). "Characteristics of the psychotropic spectrum of action of mebicar". Biulleten' eksperimental'noi biologii i meditsiny. 89 (5): 568–70. PMID 6104993.
↑ ^3.0 ^3.1 Val'Dman, A. V.; Zaikonnikova, I. V.; Kozlovskaya, M. M.; Zimakova, I. E. (1980). "A study of the spectrum of psychotropic action of mebicar". Bulletin of Experimental Biology and Medicine. 89 (5): 621. doi:10.1007/BF00835799.
↑ Mkrtchian, VR; Kozhokova, LZ (2012). "Adaptol--verges of possible". Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy (5): 125–33. PMID 23534281.
↑ Chutko, LS; Rozhkova, AV; Sidorenko, VA; Surushkina, SIu; Tursunova, KB (2012). "Generalized anxiety disorder: Psychosomatic aspects and treatment approaches". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 112 (1): 40–4. PMID 22678674.
↑ Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Kuzovenkova, MP (2010). "Asthenic disorders in children". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 110 (11 Pt 1): 26–9. PMID 21183919.
↑ Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Sergeev, AV (2009). "Adaptol in the treatment of ADHD". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 109 (8): 45–8. PMID 19738569.

Template:Anxiolytics

[olainfarm-1] 1.0 ^1.1 ^1.2 Adaptol product summary http://olainfarm.lv/en/prescription-drugs/adaptol-3

[Missingor-2] 2.0 ^2.1 Val'Dman, AV; Zaikonnikova, IV; Kozlovskaia, MM; Zimakova, IE (1980). "Characteristics of the psychotropic spectrum of action of mebicar". Biulleten' eksperimental'noi biologii i meditsiny. 89 (5): 568–70. PMID 6104993.

[DoiBFMissing-3] 3.0 ^3.1 Val'Dman, A. V.; Zaikonnikova, I. V.; Kozlovskaya, M. M.; Zimakova, I. E. (1980). "A study of the spectrum of psychotropic action of mebicar". Bulletin of Experimental Biology and Medicine. 89 (5): 621. doi:10.1007/BF00835799.

[4] Mkrtchian, VR; Kozhokova, LZ (2012). "Adaptol--verges of possible". Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy (5): 125–33. PMID 23534281.

[5] Chutko, LS; Rozhkova, AV; Sidorenko, VA; Surushkina, SIu; Tursunova, KB (2012). "Generalized anxiety disorder: Psychosomatic aspects and treatment approaches". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 112 (1): 40–4. PMID 22678674.

[6] Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Kuzovenkova, MP (2010). "Asthenic disorders in children". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 110 (11 Pt 1): 26–9. PMID 21183919.

[7] Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Sergeev, AV (2009). "Adaptol in the treatment of ADHD". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 109 (8): 45–8. PMID 19738569.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Legal status

Legal status	US: Not approved
Identifiers
IUPAC name 1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione
CAS Number	10095-06-4
PubChem CID	122282
ChemSpider	109042
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₈H₁₄N₄O₂
Molar mass	198.222 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C2C(N(C1=O)C)N(C(=O)N2C)C
InChI InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3 Key:XIUUSFJTJXFNGH-UHFFFAOYSA-N

Mebicar

Overview

References

Navigation menu